• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, and IGME

    10/23/25 4:16:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMRA alert in real time by email

    Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, and IGME.

    Fund

    Ticker

    Distribution

    Per Share

    Distribution

    Rate

    30-Day SEC

    Yield

    Return of

    Capital

    Ex-Date /

    Record Date

    Payment Date

    1-Month

    Return

    1-Year

    Return

    Since

    Inception

    Return

    Bitwise MSTR

    Option Income Strategy ETF

    IMST

    $2.88888

    120.08%

    0.00%

    100%

    10/24/2025

    10/28/2025

    -16.11%

    N/A

    -11.74%

    Bitwise COIN

    Option Income Strategy ETF

    ICOI

    $3.93547

    150.20%

    0.00%

    100%

    10/24/2025

    10/28/2025

    -7.64%

    N/A

    18.85%

    Bitwise MARA

    Option Income Strategy ETF

    IMRA

    $3.01242

    100.42%

    0.00%

    100%

    10/24/2025

    10/28/2025

    1.96%

    N/A

    16.06%

    Bitwise GME

    Option Income Strategy ETF

    IGME

    $2.77765

    100.21%

    0.00%

    100%

    10/24/2025

    10/28/2025

    -12.83%

    N/A

    -16.83%

    The Distribution Rate shown is as of 4 p.m. ET on October 23, 2025. The Distribution Rate is the annual rate an investor would receive if the most recently declared distribution, which includes option income, remained the same going forward. The Distribution Rate is calculated by multiplying an ETF's Distribution per Share by twelve (12), and dividing the resulting amount by the ETF's most recent NAV. The Distribution Rate represents a single distribution from the ETF and does not represent its total return. The distribution may include a combination of ordinary dividends, capital gain, and return of investor capital, which may decrease a fund's NAV and trading price over time. As a result, an investor may suffer significant losses to their investment. The Return of Capital percentage is the estimated portion of the distribution that represents an investor's original investment. Future distributions may differ significantly and are not guaranteed. The 30-day SEC yield reflects the dividends and interest earned during the previous month, after deducting the fund's expenses. This is also referred to as the "standardized yield" and provides an annualized estimate of what an investor would earn in yield over a 12-month period, assuming the fund continues to earn at the same rate.

    Performance data quoted represents past performance and is no guarantee of future results. Short-term performance, in particular, is not a good indication of the fund's future performance, and an investment should not be made based solely on returns. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the original cost. Returns for periods of one year or less are not annualized. For the most recent month-end performance, please call 1-415-707-3663.

    The net expense ratio for each Fund is 0.98%. (The gross expense ratio for ICOI and IMST is 0.99%, with a fee waiver in place through April 2, 2027.)

    Risks and Important Information

    Carefully consider the investment objectives, risk factors, charges, and expenses of the Bitwise COIN Option Income Strategy ETF (ICOI), Bitwise GME Option Income Strategy ETF (IGME), Bitwise MARA Option Income Strategy ETF (IMRA), and Bitwise MSTR Option Income Strategy ETF (IMST) (each a "Fund" and together the "Funds") before investing. This and additional information can be found in each Fund's full or summary prospectus, which may be obtained by visiting: for ICOI, icoietf.com; for IGME, igmeetf.com; for IMRA, imraetf.com; for IMST, imstetf.com. Investors should read it carefully before investing.

    An investment in a Fund is not an investment in the underlying security. The Funds do not directly invest directly in shares of COIN, GME, MARA, or MSTR. Fund shareholders are not entitled to any dividends from the underlying security. A Fund's strategy is subject to all potential losses if shares of the underlying security decrease in value, which may not be offset by income received by the Fund.

    Market Risk. Market risk is the risk that a particular security, or Fund Shares in general, may fall in value. Securities are subject to market fluctuations caused by such factors as economic, political, regulatory or market developments, changes in interest rates and perceived trends in securities prices.

    Covered Call Strategy Risk. A covered call strategy involves writing (selling) covered call options in return for the receipt of premiums. The seller of the option gives up the opportunity to benefit from price increases in the underlying instrument above the exercise price of the options but continues to bear the risk of underlying instrument price declines. The premiums received from the options may not be sufficient to offset any losses sustained from underlying instrument price declines over time.

    The covered call strategy utilized by the Funds is "synthetic" because the Funds' exposure to the price return of the underlying security is derived through options exposure, rather than direct holdings of the shares of the underlying security. Because such exposure is synthetic, it is possible that the Fund's participation in the price return of the underlying security may not be as precise as if the Fund were directly holding shares of the underlying security.

    Issuer-Specific Risks. Issuer-specific attributes may cause an investment held by the Fund to be more volatile than the market generally. The value of an individual security or particular type of security may be more volatile than the market as a whole and may perform differently from the value of the market as a whole.

    Equity Securities Risk. Equity securities are subject to changes in value, and their values may be more volatile than those of other asset classes.

    Digital Assets Risk. Coinbase, GameStop Corp, MARA Holdings, and Strategy (each a "Company" and together the "Companies") may have substantial holdings of bitcoin and other digital assets. Accordingly, it is subject to the risks associated with such holdings. Bitcoin is a relatively new innovation and the market for bitcoin is subject to rapid price swings, changes and uncertainty. Bitcoin is subject to the risk of fraud, theft, manipulation or security failures, operational or other problems that impact the digital asset trading venues on which bitcoin trades. The realization of any of these risks could result in a decline in the acceptance of bitcoin and consequently a reduction in the value of bitcoin and shares of COIN, GME, MARA, or MSTR.

    Custody Risk. Security breaches, computer malware and computer hacking attacks have been a prevalent concern in relation to digital assets. The bitcoin held by the Companies will likely be an appealing target to hackers or malware distributors seeking to destroy, damage or steal bitcoins. To the extent that any Company is unable to identify and mitigate or stop new security threats or otherwise adapt to technological changes in the digital asset industry, that Company's bitcoins may be subject to theft, loss, destruction or other attack.

    Digital Asset Regulatory Risk. There is a lack of consensus regarding the regulation of digital assets, including bitcoin, and their markets. Ongoing and future regulatory actions with respect to digital assets generally or bitcoin in particular may alter, perhaps to a materially adverse extent, the nature of an investment in the shares of the underlying security or the ability of the Companies to continue to operate.

    Concentration Risk. The Fund is susceptible to an increased risk of loss, including losses due to adverse events that affect the Fund's investments more than the market as a whole, to the extent that the Fund's investments are concentrated in investments that provide exposure to the underlying securities and the industry to which they are assigned.

    Derivatives Risk. The use of derivative instruments involves risks different from, or possibly greater than, the risks associated with investing directly in securities and other traditional investments. Derivative prices are highly volatile and may fluctuate substantially during a short period of time. Trading derivative instruments involves risks different from, or possibly greater than, the risks associated with investing directly in securities. The use of leverage may cause the Fund to liquidate portfolio positions when it would not be advantageous to do so in order to satisfy its obligations or to meet regulatory or contractual requirements for derivatives. The use of derivatives can magnify potential for gain or loss and, therefore, amplify the effects of market volatility on share price.

    New Fund Risk. The Fund is a recently organized investment company with a limited operating history. As a result, prospective investors have a limited track record or history on which to base their investment decision.

    Options Risk. The use of options involves investment strategies and risks different from those associated with ordinary portfolio securities transactions and depends on the ability of the Fund's portfolio managers to forecast market movements correctly. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in the value of the underlying instrument, or in interest or currency exchange rates, including the anticipated volatility, which in turn are affected by fiscal and monetary policies and by national and international political and economic events.

    Nondiversification Risk. The Funds are nondiversified and may hold a smaller number of portfolio securities than many other products. To the extent any Fund invests in a relatively small number of issuers, a decline in the market value of a particular security held by the Fund may affect its value more than if it invested in a larger number of issuers.

    Bitwise Funds Trust ETFs are distributed by Foreside Fund Services, LLC, which is not affiliated with Bitwise or any of its affiliates.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251023623734/en/

    Media Contact

    Tova Kaufmann

    [email protected]

    Get the next $IMRA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMRA

    DatePrice TargetRatingAnalyst
    1/6/2022$12.00 → $4.00Equal-Weight
    Morgan Stanley
    11/30/2021$10.00Buy
    HC Wainwright & Co.
    8/11/2021$33.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $IMRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, and IGME

    Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, and IGME. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since Inception Return Bitwise MSTR Option Income Strategy ETF IMST $2.88888 120.08% 0.00% 100% 10/24/2025 10/28/2025 -16.11% N/A -11.74% Bitwise COIN Option Income Strategy ETF ICOI $3.93547 150.20% 0.00

    10/23/25 4:16:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imara Announces Stockholder Approval of Merger With Enliven

    -- Combined Company to Trade on Nasdaq Under Ticker "ELVN" ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA) today announced the results of the special meeting of its stockholders held on February 22, 2023. At the special meeting, Imara's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Imara's common stock to the stockholders of Enliven Therapeutics, Inc. ("Enliven") pursuant to the terms of the Agreement and Plan of Merger, dated as of October 13, 2022, pursuant to which a direct, wholly-owned subsidiary of Imara will merge with and into

    2/22/23 4:01:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lifshitz Law PLLC Announces Investigations of IMRA, AGFS, USER, and PEBO

    NEW YORK, NY / ACCESSWIRE / November 23, 2022 / Lifshitz Law PLLC:Imara Inc. (NASDAQ:IMRA)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of IMRA and Enliven Therapeutics, Inc.If you are an IMRA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected] Solutions, Inc. (NASDAQ:AGFS)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of AGFS to Paine Schwartz Partners for $3.00 per share in cash.If you a

    11/23/22 7:48:00 PM ET
    $AGFS
    $IMRA
    $PEBO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Banks
    Finance

    $IMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley reiterated coverage on Imara with a new price target

    Morgan Stanley reiterated coverage of Imara with a rating of Equal-Weight and set a new price target of $4.00 from $12.00 previously

    1/6/22 10:34:33 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. initiated coverage on Imara with a new price target

    HC Wainwright & Co. initiated coverage of Imara with a rating of Buy and set a new price target of $10.00

    11/30/21 7:23:31 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imara downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Imara from Overweight to Equal-Weight and set a new price target of $12.00 from $33.00 previously

    8/11/21 6:17:27 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    SEC Filings

    View All

    SEC Form 144 filed by IMARA Inc.

    144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/15/24 5:04:57 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by IMARA Inc.

    144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

    12/20/23 6:06:54 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by IMARA Inc.

    144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

    12/19/23 5:27:50 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    5am Partners Vi, Llc sold $12,292,500 worth of shares (825,000 units at $14.90) (SEC Form 4)

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/16/24 4:15:31 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Phillips Andrew John

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 9:04:08 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Patel Anish

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 9:02:21 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    Leadership Updates

    Live Leadership Updates

    View All

    Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

    Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara's new Vice President of Clinical Development BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, announced data today in three preclinical mouse models of heart failure with preserved ejection fraction (HFpEF) treated with tovinontrine (IMR-687). Sele

    11/8/21 7:00:00 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors

    BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the election of Laura A. Williams, M.D., MPH to its Board of Directors. Dr. Williams brings 25 years of early-to-late-stage drug development experience across multiple therapeutic areas, as well as expertise in patient advocacy to Imara. "We're thrilled to welcome Dr. Williams to our Board," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "In addition to her significant experience leading clinical

    6/30/21 7:00:00 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer

    BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of Kenneth Attie, M.D. as Senior Vice President and Chief Medical Officer. Dr. Attie joins Imara with over 30 years of experience within academia and the biopharmaceutical industry, most recently at Acceleron Pharma, Inc. where he led global clinical development efforts that led to the recent FDA and EMA approvals of a new treatment for patients with rare anemias, including beta-thalassemia.  “We are exc

    1/20/21 7:00:00 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    Financials

    Live finance-specific insights

    View All

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, and IGME

    Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, and IGME. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since Inception Return Bitwise MSTR Option Income Strategy ETF IMST $2.88888 120.08% 0.00% 100% 10/24/2025 10/28/2025 -16.11% N/A -11.74% Bitwise COIN Option Income Strategy ETF ICOI $3.93547 150.20% 0.00

    10/23/25 4:16:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Enliven Therapeutics and Imara Announce Merger Agreement

    Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host co

    10/13/22 4:35:22 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imara Reports Full Year 2021 Financial Results and Business Highlights

    Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary endpoint of Ardent Phase 2b trial in sickle cell disease to reductions in annualized rate of VOCs at written request of the FDA Added clinical indication for tovinontrine to include the treatment of HFpEF; anticipate first subject dosing in Phase 2 trial in second quarter of 2022 Expanded pipeline with addition of IMR-261, an oral, clinic-ready Nrf2 activator with potential indications in hemoglobin and iron overload disorders Company to host conference call and live webcast today at 8:30 AM ET BO

    3/15/22 7:00:00 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by IMARA Inc. (Amendment)

    SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/16/24 4:15:28 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

    SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/14/24 8:53:21 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

    SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/14/24 4:58:16 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care